HSPA9 and ovarian carcinoma: Thus, inhibiting the expression of mortalin leads to decreased proliferation and migration and increased sensitivity to cisplatin in ovarian cancer cells [9,10]; however, the upstream regulation of mortalin is not yet fully understood.